Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age

被引:44
作者
Nakamura, Y
Sekine, I
Furuse, K
Saijo, N
机构
[1] Natl Canc Ctr, Dept Med Oncol, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Kinki Cent Hosp Chest Dis, Dept Internal Med, Osaka 5918025, Japan
关键词
paclitaxel; non-small-cell lung cancer; elderly; chemotherapy;
D O I
10.1007/s002800000143
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). Methods: We compared the toxicity, response, survival and pharmacokinetic parameters between patients between 70 and 75 years of age (elderly group) and those under 70 years of age (younger group) who were enrolled in two phase II trials of 3-h infusions of paclitaxel. Results: A total of 120 patients were eligible for the studies, of whom 28 were in the elderly group and 92 in the younger group. Neutropenia was the most prominent toxicity. Grade 3-4 neutropenia was recorded in 89.3% of the elderly group and in 73.9% of the younger group (P = 0.13). Other hematological and non-hematological toxicities were mild regardless of age. Tumor response (46.4% vs 32.2%) and median survival time (9.8 months vs 6.8 months) did not differ between the elderly and younger groups. Pharmacokinetic studies failed to detect any difference between the two groups. Conclusion: Intravenous 3-h infusions of paclitaxel are as safe and effective in elderly patients with NSCLC as in younger patients.
引用
收藏
页码:114 / 118
页数:5
相关论文
共 31 条
[1]   Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 - Response [J].
Amirimani, B ;
Walker, AH ;
Weber, BL ;
Rebbeck, TR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1588-1590
[2]   Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [J].
Ando, Y ;
Tateishi, T ;
Sekido, Y ;
Yamamoto, T ;
Satoh, T ;
Hasegawa, Y ;
Kobayashi, S ;
Katsumata, Y ;
Shimokata, K ;
Saito, H .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1587-1588
[3]   INFLUENCE OF LIVER-DISEASE AND ENVIRONMENTAL-FACTORS ON HEPATIC MONO-OXYGENASE ACTIVITY INVITRO [J].
BRODIE, MJ ;
BOOBIS, AR ;
BULPITT, CJ ;
DAVIES, DS .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 20 (01) :39-46
[4]   PHASE-II STUDY OF TAXOL, MERBARONE, AND PIROXANTRONE IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - THE EASTERN COOPERATIVE ONCOLOGY GROUP RESULTS [J].
CHANG, AY ;
KIM, K ;
GLICK, J ;
ANDERSON, T ;
KARP, D ;
JOHNSON, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :388-394
[5]  
Custer RP, 1931, J LAB CLIN MED, V17, P960
[6]   EFFECT OF AGE ON THERAPEUTIC OUTCOME IN ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
DIXON, DO ;
NEILAN, B ;
JONES, SE ;
LIPSCHITZ, DA ;
MILLER, TP ;
GROZEA, PN ;
WILSON, HE .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :295-305
[7]  
EGORIN MJ, 1993, SEMIN ONCOL, V20, P43
[8]   TREATMENT OUTCOME IN HODGKINS-DISEASE IN PATIENTS ABOVE THE AGE OF 60 - A POPULATION-BASED STUDY [J].
ENBLAD, G ;
GLIMELIUS, B ;
SUNDSTROM, C .
ANNALS OF ONCOLOGY, 1991, 2 (04) :297-302
[9]  
Furuse K, 1997, ONCOLOGY, V54, P298
[10]  
GOTTLIEB D, 1987, CANCER, V60, P1439, DOI 10.1002/1097-0142(19871001)60:7<1439::AID-CNCR2820600705>3.0.CO